HomeProfiles › Vivek Ramaswamy

Companies Owned by Vivek Ramaswamy: Stakes, Investments & Exits

Last updated: Sep-2026
Net worth $3.5 billion Founder and InvestorBiotechnology and Asset Management
🏢1 Companies 📊2 Minority Stakes 💼0 Investments 🚪2 Exits 💰$3.5 billion Net Worth
Overview

Portfolio Overview

1Controlled Companies
2Minority Holdings
0Other Investments
2Former Companies
$3.5 billionNet Worth | Sep-2026

Ownership & Control Structure

Vivek Ramaswamy
Direct ownership
Direct ownership
Direct ownership
Holding EntityTypePurpose
Virtuous IndustriesHolding companyInvestment holdings

What Companies Does Vivek Ramaswamy Own?

Vivek Ramaswamy owns substantial minority positions in Roivant Sciences and Strive. He founded Roivant in 2014 but no longer manages the biotechnology company. A February 2026 ownership filing reported beneficial ownership of about 48.4 million Roivant shares and options, equal to 6.8% at December 31, 2025. The holding combines restricted awards and exercisable options, so it is not equivalent to the same number of freely tradable shares.

At Strive, an August 26, 2026 Schedule 13D amendment reported 5.69 million Class A-equivalent shares for Ramaswamy, representing 6.6%, plus 106,245 shares held through Virtuous Industries. Strive now operates as a public asset manager and Bitcoin-treasury business. Ramaswamy is a significant shareholder and founder, but the reported percentage does not give him unilateral corporate control.

BuzzFeed is a former investment. Ramaswamy accumulated an activist stake in 2024, then disclosed a complete exit on May 12, 2026 after selling 3.13 million shares and related securities. Campus Venture Network is also former; the student-networking company was sold in 2009. Political candidacy, books and speaking activity may produce income, but they are not separate owned companies.

The current ownership map is consequently narrow but economically substantial. Roivant and Strive account for the visible public-equity exposure, while Virtuous Industries is a personal holding vehicle rather than another operating enterprise. We separate Ramaswamy's founder history from present authority: he can benefit materially from share-price movements and exercise shareholder rights, but independent boards and executives run both public companies. The completed BuzzFeed disposal belongs with former investments, not in a current-company count.

This distinction changes the risk analysis. Ramaswamy's wealth is easier to mark than a private founder fortune because both principal holdings trade publicly, yet options, restricted stock and entity-held shares have different economics. Political activity may also limit his practical ability to trade or influence management. Ownership is real; day-to-day control is not.

Portfolio Analysis

Ramaswamy's portfolio is concentrated in two public equities with unrelated operating engines but overlapping market volatility. Roivant carries drug-development risk; Strive combines fee revenue with Bitcoin exposure. Quoted prices make the holdings easier to mark than private companies, yet concentration can produce large daily changes in wealth.

Roivant remains the higher-quality core because it has a longer operating history and multiple pharmaceutical assets. Clinical failures can destroy value quickly, while successful approvals or partnerships can create asymmetric upside. Strive adds a treasury strategy whose gains depend heavily on Bitcoin prices and access to capital markets.

The completed BuzzFeed sale reduced a distracting activist position before the 2026 election. We see that exit as simplification, not diversification. A more balanced portfolio would require assets whose cash flows are less dependent on biotechnology milestones, cryptocurrency prices and founder-linked public scrutiny.

Roivant supplies idiosyncratic drug-development upside, whereas Strive adds macro sensitivity through Bitcoin and capital issuance. Those drivers are different, but both reward risk appetite and can sell off sharply when financing conditions tighten. We therefore see less diversification than two industry labels suggest. The portfolio lacks a large defensive cash-flow asset able to offset either drawdown.

The Roivant position has better underlying breadth because several therapies and subsidiaries can contribute value. Even so, correlations rise when the market discounts biotechnology as a whole or when funding becomes expensive. Strive's quoted net asset value may appear transparent, yet investors must account for liabilities, operating costs and the fully diluted share count. Price-to-Bitcoin exposure is not equivalent to owning Bitcoin directly.

Cash reserves outside these companies determine Ramaswamy's ability to hold through volatility. Selling a large founder block during weakness could pressure price and create tax costs. A measured diversification program would use trading plans and liquid proceeds rather than borrowing aggressively against volatile shares. The BuzzFeed exit simplified the portfolio, but it did not solve its concentration.

Business Profile

Ramaswamy's wealth comes from founding equity rather than a diversified operating conglomerate. Roivant develops and commercializes medicines through a portfolio model. Its value depends on clinical results, regulatory decisions and the economics of partnered drugs, which can create sharp gains or losses around individual events.

Strive adds a very different risk factor. The public company combines asset-management operations with substantial Bitcoin exposure. Management fees can recur, while a treasury strategy introduces commodity-like volatility, financing risk and potential dilution. Ramaswamy's August 2026 percentage fell after share issuance even though he did not report a corresponding sale.

We view the portfolio as liquid in quotation but constrained in practice. Public prices provide visible marks, yet restricted awards, options, taxes and trading limitations affect realizable value. His 2026 political role also increases scrutiny around governance, conflicts and the timing of securities transactions.

Roivant's portfolio model seeks to acquire or develop drug programs that larger organizations may not prioritize, then create focused teams around them. The financial attraction is asymmetric: one successful therapy or partnership can repay substantial development spending. The cost is milestone volatility, because clinical setbacks and regulatory decisions can remove years of expected value in a single announcement.

Strive now exposes shareholders to two businesses that deserve separate treatment. Asset management can produce recurring fees tied to assets under management, client retention and pricing. A Bitcoin treasury creates balance-sheet appreciation or loss, funded through equity or debt that changes per-share outcomes. We track fee economics and Bitcoin per diluted share independently because a rising cryptocurrency price can conceal dilution or weak operating performance.

Ramaswamy's personal business profile is therefore closer to a concentrated public-market holding company than an active operating conglomerate. His advantage is founder access and capital-markets visibility. His vulnerability is that both major stakes respond to binary or highly volatile drivers. Diversification would have to come from realized sales and new assets, not from the superficial difference between biotechnology and financial services.

Ownership

Controlled Businesses

Companies Currently Owned or Controlled

1 held
CompanyRelationshipEquityRoleSince
Virtuous Industries LLCControlled holding entityN/AManagerN/A

Control & Capital Allocation Analysis

Founder status does not equal current control. Ramaswamy owns minority positions in Roivant and Strive and no longer holds their principal executive roles. Boards and current management allocate corporate capital. His influence comes from share ownership, history and public visibility rather than majority voting power.

Beneficial-ownership filings require careful reading. Options, restricted awards and shares held through entities can count toward reported percentages while carrying different vesting, tax and voting attributes. Strive's issuance activity also shows how dilution can reduce ownership without a sale.

Political office would heighten conflict-management requirements. Trading plans, recusal practices and disclosure timing would become important safeguards. We would discount any valuation that assumes Ramaswamy can direct corporate policy merely because he founded the company.

At Roivant, a 6.8% beneficial position can command attention without carrying decisive votes. Options and restricted awards may increase economic exposure while delaying voting power or liquidity. Board composition, executive incentives and other large shareholders determine strategy. Founder reputation can influence debate, but it cannot substitute for formal authority.

Strive presents a moving denominator. Capital issuance can reduce Ramaswamy's percentage even when his share count is unchanged, and future Bitcoin purchases may require further financing. Participation rights become important if he wants to preserve exposure. We examine dilution alongside treasury growth because corporate scale only benefits an owner when value per share rises.

Public political activity adds a governance overlay uncommon in ordinary founder profiles. Recusals, securities reporting and prearranged trading plans protect against conflicts between personal liquidity and public decisions. Our valuation does not assign a control premium merely because Ramaswamy founded the companies. A significant minority discount remains appropriate unless voting arrangements provide rights beyond the disclosed percentages. Independent directors also need explicit, clear authority to review related transactions, financing choices and any use of the founder's political identity.

Investments

Minority Stakes, Investments & Brands

Minority Ownership Stakes

2 positions
CompanyStakeRoleValue
Roivant SciencesN/AMinority InvestorN/A
Strive Inc.N/AMinority InvestorN/A

Minority-Stake & Investment Analysis

The BuzzFeed campaign showed an activist style built around public pressure and strategic proposals. The 2026 exit closed that experiment before a disclosed long-term operational turnaround was achieved. Marketable shares offered liquidity that private venture positions would not.

Strive is both an investment and a company he helped create. Its Bitcoin accumulation can amplify equity returns when crypto rises, but financing new purchases through shares or debt can transfer value among shareholders. The relevant measures are Bitcoin per share, fee-earning assets and corporate obligations.

We prefer separating investment skill from founder wealth. Roivant appreciation reflects years of company development, not a repeatable public-stock strategy. A fuller judgment requires realized returns, acquisition costs and taxes across multiple independent positions.

BuzzFeed illustrates both the reach and limitation of activist investing through a public platform. Ramaswamy could articulate strategic demands and attract attention, but a minority shareholder cannot impose an operational plan without board support or a broader voting coalition. Exiting in May 2026 removed the cost of a prolonged campaign and freed capital for other uses. It also ended the possibility of benefiting from a later turnaround.

Roivant is fundamentally different from a conventional stock selection. Ramaswamy helped create the enterprise and accumulated equity through founder economics, awards and options. Its performance says much about entrepreneurial value creation, but less about his ability to repeat returns across unrelated securities. We keep those two skills separate when evaluating the portfolio.

Strive's treasury strategy should be judged on per-share compounding. Issuing stock above net asset value can be accretive; issuing too cheaply transfers value to new buyers. Debt introduces interest and refinancing obligations that persist through crypto downturns. A disciplined investment case requires management fees to cover more of the corporate cost base so shareholders are not relying exclusively on favorable Bitcoin markets.

Deals

Transactions, Acquisitions & Exits

Former Companies & Exits

CompanyFormer RelationshipExitBuyer & ValueOutcome
BuzzFeedFormer activist investorN/AN/A
N/A
N/A
Campus Venture NetworkCo-founderN/AN/A
N/A
N/A

Transaction & Exit Analysis

Campus Venture Network provided an early entrepreneurial exit in 2009, though public terms are limited. BuzzFeed offers the clearer recent event: Ramaswamy sold the remaining 3.13 million securities on May 12, 2026 and reported 0% ownership.

The BuzzFeed outcome should be measured against purchase cost and sale proceeds, neither of which is fully summarized by the final filing. A complete exit removes governance and reputational exposure while ending any upside from subsequent transactions.

Future liquidity will probably come from planned Roivant sales or Strive transactions rather than company takeovers. We would watch Form 4 filings and tax-aware trading plans. Gradual diversification may protect wealth better than waiting for a single headline exit.

Campus Venture Network and BuzzFeed represent two different types of realization. The 2009 company sale was an entrepreneurial exit from an operating venture; the May 2026 BuzzFeed filing documented the liquidation of a public activist stake. Neither should be conflated with the much larger unrealized value still held in Roivant and Strive.

BuzzFeed's final 0% ownership disclosure provides certainty about status but not the quality of the return. Purchase prices, interim trades, taxes and financing would be needed to calculate performance. We can still infer a portfolio benefit: the disposal removed a small, attention-intensive holding before a major political campaign and reduced the number of public-company conflicts.

Future exits require more careful sequencing because the remaining blocks are larger. Rule-based sales can reduce concentration without surprising the market, while a strategic block transaction may achieve speed at a discount. Full disposal would sacrifice founder-linked upside and could be interpreted as a change in conviction. The appropriate goal is not a dramatic exit but a liquidity program that protects both price and flexibility.

Wealth

Wealth, Income & Financial Trends

Net Worth & Sources of Wealth

$3.5 billionNet Worth | Sep-2026
N/APortfolio Value | N/A
N/AAnnual Income | N/A
RoivantPrimary Source of Wealth

Historical Financial Trends

Net Worth · Five-Year Trend

Sources of Wealth

Wealth & Income Analysis

The rise from $630 million in 2023 to $3.5 billion in September 2026 largely reflects equity-market appreciation and updated share counts. That appreciation did not deliver billions of dollars in cash to Ramaswamy. Selling concentrated positions could create taxes, price pressure and disclosure obligations.

Options require strike-price deductions, and restricted awards may vest over time. A simple share-count multiplication can therefore overstate realizable wealth. Strive's volatile treasury exposure introduces another layer between corporate asset value and personal net worth.

We would distinguish liquid reserves from quoted founder equity when assessing financial capacity. Political spending, new investments or diversification must be funded with cash or sales. The headline estimate is useful directionally, but the balance sheet remains sensitive to two public securities.

The $3.5 billion estimate can change rapidly because it is tied to public prices and a complex beneficial share count. Roivant options have exercise costs, awards may vest over time, and entity-held Strive shares still belong within a wider legal and tax structure. Market capitalization offers a daily reference point, but realizable wealth is lower after those deductions.

Concentrated liquidity has a reflexive risk. A large sale can signal reduced confidence, expand public float and pressure the price used to calculate the remaining stake. Borrowing against shares avoids an immediate sale but introduces margin risk during volatility. We prefer gradual, disclosed diversification funded from vested holdings over leverage that could force transactions at the worst time.

Political ambitions can increase cash needs while reducing flexibility around trading. The strongest balance-sheet position would combine a material liquid reserve with continuing upside in Roivant and Strive. Without that reserve, personal financial capacity remains dependent on two securities whose valuations respond to events outside Ramaswamy's control. The headline fortune is substantial, but its stability through market cycles is weaker than the dollar amount alone implies.

History

Portfolio Development Over Time

Business Ownership Timeline

2009
First exit
Campus Venture Network was sold.
2014
Roivant founded
Ramaswamy launched the biotechnology company.
2022
Strive founded
The asset manager began operating.
2026-05-12
BuzzFeed exit
He sold the remaining stake.
2026-08-26
Strive filing
Ownership was reported at 6.6%.

Business Trajectory Analysis

Roivant clinical and commercial milestones will remain the largest driver of Ramaswamy's wealth. The company can create value through approvals, royalties, partnerships and asset sales, but development setbacks can quickly reverse market gains.

Strive's direction is harder to separate from capital-market conditions. Bitcoin appreciation can raise net asset value, while dilution and financing costs determine how much reaches each share. Asset-management fees need to become meaningful enough to reduce treasury dependence.

We expect political activity to limit operational involvement and increase disclosure scrutiny. A disciplined transition would use independent managers, preset trading arrangements and fewer activist side positions. That structure could preserve founder wealth without confusing public office, corporate governance and personal investing.

Roivant's pipeline will continue to dominate the personal balance sheet. Partnerships, approvals or asset sales can crystallize value, while failed trials can remove it. We focus on milestone quality and cash runway rather than the number of programs, since weak projects consume resources and dilute attention.

Strive must prove that it is more than a leveraged expression of cryptocurrency prices. Growth in fee-earning assets, client retention and operating discipline could support a more durable valuation. Repeated equity issuance without per-share improvement would undermine that case even if total Bitcoin holdings rise.

Public service would make independence a strategic asset. Preset trading arrangements, empowered boards and limited involvement in capital decisions can protect the companies from political distraction. Over time, Ramaswamy can reduce portfolio fragility by converting part of the quoted gains into assets with steadier cash generation. Until that happens, biotechnology milestones and Bitcoin remain the two variables that matter most.

Frequently Asked Questions

What companies does Vivek Ramaswamy own in 2026?

As of September 14, 2026, Ramaswamy controlled Virtuous Industries and held large minority positions in Roivant Sciences and Strive Inc. He no longer held the BuzzFeed position accumulated in 2024.

How much of Roivant does Vivek Ramaswamy own?

A February 2026 filing reported about 48.4 million beneficially owned Roivant shares and options, equal to 6.8% as of December 31, 2025. The total included restricted awards and options.

How much of Strive does Vivek Ramaswamy own?

The Schedule 13D amendment filed August 26, 2026 reported 5,693,897 Class A-equivalent shares for Ramaswamy, or 6.6%, plus 106,245 shares held by Virtuous Industries.

Does Vivek Ramaswamy still own BuzzFeed?

No. A filing reported that he sold 3,129,779 BuzzFeed shares and related securities on May 12, 2026, reducing his beneficial ownership from an activist position to 0%.

What is Vivek Ramaswamy's net worth?

Forbes Ramaswamy's net worth at $3.5 billion on September 14, 2026. The figure moves with Roivant and Strive prices and includes securities whose liquidity and tax treatment differ.

Related Profiles, Companies & Articles